Држава: Велика Британија
Језик: Енглески
Извор: MHRA (Medicines & Healthcare Products Regulatory Agency)
Etoposide phosphate
Neon Healthcare Ltd
L01CB01
Etoposide phosphate
100mg
Powder for solution for injection
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 08010400; GTIN: 5012712002192
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT ETOPOPHOS ™ 100 MG POWDER FOR SOLUTION FOR INJECTION Etoposide phosphate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What ETOPOPHOS is and what it is used for 2. What you need to know before you are given ETOPOPHOS 3. How you will be given ETOPOPHOS 4. Possible Side Effects 5. How to store ETOPOPHOS 6. Contents of the pack and other information 1. WHAT ETOPOPHOS IS AND WHAT IT IS USED FOR The name of your medicine is ETOPOPHOS. Each vial contains etoposide phosphate equivalent to etoposide 100 mg as the active ingredient. Etoposide phosphate belongs to a group of medicines called cytostatics which are used in the treatment of cancer. ETOPOPHOS is used to in the treatment of certain types of cancer in adults: - testicular cancer - small cell lung cancer - cancer of the blood (acute myeloid leukaemia) - tumour in the lymphatic system (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma) - reproductive system cancers (gestational trophoblastic neoplasia and ovarian cancer) ETOPOPHOS is used in the treatment of certain types of cancers in children: - cancer of the blood (acute myeloid leukaemia) - tumour in the lymphatic system (Hodgkin’s lymphoma, non-Hodgkin’s lymphoma) The exact reason why you have been prescribed ETOPOPHOS is best discussed with your doctor. 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN ETOPOPHOS DO NOT RECEIVE ETOPOPHOS: - If you are allergic to etoposide or any of the other ingredients of this medicine (listed in section 6). - If y Прочитајте комплетан документ
OBJECT 1 ETOPOPHOS 100MG POWDER FOR SOLUTION FOR INJECTION Summary of Product Characteristics Updated 23-Oct-2017 | Bristol-Myers Squibb Pharmaceuticals limited 1. Name of the medicinal product ETOPOPHOS 100mg Powder for Solution for Injection 2. Qualitative and quantitative composition Each vial contains 113.6 mg etoposide phosphate equivalent to 100 mg etoposide. For the full list of excipients, see section 6.1. 3. Pharmaceutical form Powder for solution for injection. White to off-white dry powder. 4. Clinical particulars 4.1 Therapeutic indications TESTICULAR CANCER ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of first line, recurrent or refractory testicular cancer in adults. SMALL CELL LUNG CANCER ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of small-cell lung cancer in adults. HODGKIN'S LYMPHOMA ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of Hodgkin's lymphoma in adult and paediatric patients. NON-HODGKIN'S LYMPHOMA ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of non-Hodgkin's lymphoma in adult and paediatric patients. ACUTE MYELOID LEUKAEMIA ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of acute myeloid leukaemia in adult and paediatric patients. GESTATIONAL TROPHOBLASTIC NEOPLASIA ETOPOPHOS is indicated for first line and second line therapy in combination with other approved chemotherapeutic agents for the treatment of high risk gestational trophoblastic neoplasia in adults. OVARIAN CANCER ETOPOPHOS is indicated in combination with other approved chemotherapeutic agents for the treatment of non-epithelial ovarian cancer in adults. ETOPOPHOS is indicated for the treatment of platinum-resistant/refractory epithelial ovarian cancer in adults. 4.2 Posology and method of administration ETOPOPHOS should only be administered and monitored u Прочитајте комплетан документ